Log in

NASDAQ:BPMC - Blueprint Medicines Stock Price, Forecast & News

$66.98
+3.17 (+4.97 %)
(As of 02/17/2020 02:32 AM ET)
Add
Today's Range
$63.21
Now: $66.98
$67.24
50-Day Range
$61.50
MA: $72.79
$82.22
52-Week Range
$60.60
Now: $66.98
$102.98
Volume560,260 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:BPMC
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees217
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive BPMC News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.


Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Corp (NASDAQ:BPMC) announced its earnings results on Thursday, February, 13th. The biotechnology company reported ($1.35) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.36. The biotechnology company earned $51.53 million during the quarter, compared to analyst estimates of $26 million. The company's revenue for the quarter was up 4888.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.83) EPS. View Blueprint Medicines' Earnings History.

When is Blueprint Medicines' next earnings date?

Blueprint Medicines is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Blueprint Medicines.

What price target have analysts set for BPMC?

12 equities research analysts have issued twelve-month price targets for Blueprint Medicines' stock. Their forecasts range from $70.00 to $125.00. On average, they expect Blueprint Medicines' share price to reach $104.58 in the next twelve months. This suggests a possible upside of 56.1% from the stock's current price. View Analyst Price Targets for Blueprint Medicines.

What is the consensus analysts' recommendation for Blueprint Medicines?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines.

Has Blueprint Medicines been receiving favorable news coverage?

Media headlines about BPMC stock have been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Blueprint Medicines earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Blueprint Medicines.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), Micron Technology (MU), Nektar Therapeutics (NKTR), AbbVie (ABBV), Stratasys (SSYS), Canopy Growth (CGC), Intercept Pharmaceuticals (ICPT), Ionis Pharmaceuticals (IONS), Xilinx (XLNX) and STMicroelectronics (STM).

Who are Blueprint Medicines' key executives?

Blueprint Medicines' management team includes the folowing people:
  • Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 48)
  • Mr. Alexis A. Borisy, Co-Founder & Director (Age 47)
  • Mr. Michael Landsittel, Chief Financial Officer (Age 47)
  • Ms. Kathryn Haviland, Chief Operating Officer (Age 43)
  • Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 56)

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Cadian Capital Management LP (4.00%), State Street Corp (3.81%), Westfield Capital Management Co. LP (1.57%), Eagle Asset Management Inc. (1.55%) and Perceptive Advisors LLC (1.26%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Institutional Ownership Trends for Blueprint Medicines.

Which major investors are selling Blueprint Medicines stock?

BPMC stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Pictet Asset Management Ltd., Perceptive Advisors LLC, BVF Inc. IL, Victory Capital Management Inc., Westfield Capital Management Co. LP, Victory Capital Management Inc. and Spark Investment Management LLC. Company insiders that have sold Blueprint Medicines company stock in the last year include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Insider Buying and Selling for Blueprint Medicines.

Which major investors are buying Blueprint Medicines stock?

BPMC stock was acquired by a variety of institutional investors in the last quarter, including Cadian Capital Management LP, Point72 Asset Management L.P., Candriam Luxembourg S.C.A., Credit Suisse AG, Barclays PLC, Jane Street Group LLC, Sectoral Asset Management Inc and Guggenheim Capital LLC. View Insider Buying and Selling for Blueprint Medicines.

How do I buy shares of Blueprint Medicines?

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $66.98.


MarketBeat Community Rating for Blueprint Medicines (NASDAQ BPMC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  414 (Vote Outperform)
Underperform Votes:  289 (Vote Underperform)
Total Votes:  703
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe BPMC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel